|
1
|
Hidalgo M: Pancreatic cancer. N Engl J
Med. 362:1605–1617. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Berlin J and Benson AB III: Chemotherapy:
Gemcitabine remains the standard of care for pancreatic cancer. Nat
Rev Clin Oncol. 7:135–137. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Boussouar F, Jamshidikia M, Morozumi Y,
Rousseaux S and Khochbin S: Malignant genome reprogramming by
ATAD2. Biochim Biophys Acta. 1829:1010–1014. 2103. View Article : Google Scholar
|
|
5
|
Cattaneo M, Morozumi Y, Perazza D,
Boussouar F, Jamshidikia M, Rousseaux S, Verdel A and Khochbin S:
Lessons from yeast on emerging roles of the ATAD2 protein family in
gene regulation and genome organization. Mol Cells. 37:851–856.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ogura T and Wilkinson AJ: AAA+ superfamily
ATPases: Common structure-diverse function. Genes Cells. 6:575–597.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hanson PI and Whiteheart SW: AAA+
proteins: Have engine, will work. Nat Rev Mol Cell Biol. 6:519–529.
2005. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ntranos A and Casaccia P: Bromodomains:
Translating the words of lysine acetylation into myelin injury and
repair. Neurosci Lett. 625:4–10. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zou JX, Guo L, Revenko AS, Tepper CG, Gemo
AT, Kung HJ and Chen HW: Androgen-induced coactivator ANCCA
mediates specific androgen receptor signaling in prostate cancer.
Cancer Res. 69:3339–3346. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ciró M, Prosperini E, Quarto M, Grazini U,
Walfridsson J, McBlane F, Nucifero P, Pacchiana G, Capra M,
Christensen J and Helin K: ATAD2 is a novel cofactor for MYC,
overexpressed and amplified in aggressive tumors. Cancer Res.
69:8491–8498. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hsia EY, Kalashnikova EV, Revenko AS, Zou
JX, Borowsky AD and Chen HW: Deregulated E2F and the AAA+
coregulator ANCCA drive proto-oncogene ACTR/AIB1 overexpression in
breast cancer. Mol Cancer Res. 8:183–193. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Revenko AS, Kalashnikova EV, Gemo AT, Zou
JX and Chen HW: Chromatin loading of E2F-MLL complex by
cancer-associated coregulator ANCCA via reading a specific histone
mark. Mol Cell Biol. 30:5260–5272. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Duan Z, Zou JX, Yang P, Wang Y, Borowsky
AD, Gao AC and Chen HW: Developmental and androgenic regulation of
chromatin regulators EZH2 and ANCCA/ATAD2 in the prostate Via MLL
histone methylase complex. Prostate. 73:455–466. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Caron C, Lestrat C, Marsal S, Escoffier E,
Curtet S, Virolle V, Barbry P, Debernardi A, Brambilla C, Brambilla
E, et al: Functional characterization of ATAD2 as a new
cancer/testis factor and a predictor of poor prognosis in breast
and lung cancers. Oncogene. 29:5171–5181. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zou JX, Duan Z, Wang J, Sokolov A, Xu J,
Chen CZ, Li JJ and Chen HW: Kinesin family deregulation coordinated
by bromodomain protein ANCCA and histone methyltransferase MLL for
breast cancer cell growth, survival, and tamoxifen resistance. Mol
Cancer Res. 12:539–549. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kalashnikova EV, Revenko AS, Gemo AT,
Andrews NP, Tepper CG, Zou JX, Cardiff RD, Borowsky AD and Chen HW:
ANCCA/ATAD2 overexpression identifies breast cancer patients with
poor prognosis, acting to drive proliferation and survival of
triple-negative cells through control of B-Myb and EZH2. Cancer
Res. 70:9402–9412. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fouret R, Laffaire J, Hofman P,
Beau-Faller M, Mazieres J, Validire P, Girard P, Camilleri-Bröet S,
Vaylet F, Leroy-Ladurie F, et al: A comparative and integrative
approach identifies ATPase family, AAA domain containing 2 as a
likely driver of cell proliferation in lung adenocarcinoma. Clin
Cancer Res. 18:5606–5616. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Raeder MB, Birkeland E, Trovik J, Krakstad
C, Shehata S, Schumacher S, Zack TI, Krohn A, Werner HM, Moody SE,
et al: Integrated genomic analysis of the 8q24 amplification in
endometrial cancers identifies ATAD2 as essential to MYC-dependent
cancers. PLoS One. 8:e548732013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang Y, Sun Y, Li Y, Fang Z, Wang R, Pan
Y, Hu H, Luo X, Ye T, Li H, et al: ANCCA protein expression is a
novel independent poor prognostic marker in surgically resected
lung adenocarcinoma. Ann Surg Oncol. 20 Suppl 3:S577–S582. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wu G, Liu H, He H, Wang Y, Lu X, Yu Y, Xia
S, Meng X and Liu Y: miR-372 down-regulates the oncogene ATAD2 to
influence hepatocellular carcinoma proliferation and metastasis.
BMC Cancer. 14:1072014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wan WN, Zhang YX, Wang XM, Liu YJ, Zhang
YQ, Que YH and Zhao WJ: ATAD2 is highly expressed in ovarian
carcinomas and indicates poor prognosis. Asian Pac J Cancer Prev.
15:2777–2783. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wu G, Lu X, Wang Y, He H, Meng X, Xia S,
Zhen K and Liu Y: Epigenetic high regulation of ATAD2 regulates the
Hh pathway in human hepatocellular carcinoma. Int J Oncol.
45:351–361. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hwang HW, Ha SY, Bang H and Park CK: ATAD2
as a Poor prognostic marker for hepatocellular carcinoma after
curative resection. Cancer Res Treat. 47:853–861. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zheng L, Li T, Zhang Y, Guo Y, Yao J, Dou
L and Guo K: Oncogene ATAD2 promotes cell proliferation, invasion
and migration in cervical cancer. Oncol Rep. 33:2337–2344. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shang P, Meng F, Liu Y and Chen X:
Overexpression of ANCCA/ATAD2 in endometrial carcinoma and its
correlation with tumor progression and poor prognosis. Tumour Biol.
36:4479–4485. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Krakstad C, Tangen IL, Hoivik EA, Halle
MK, Berg A, Werner HM, Ræder MB, Kusonmano K, Zou JX, Øyan AM, et
al: ATAD2 overexpression links to enrichment of B-MYB-translational
signatures and development of aggressive endometrial carcinoma.
Oncotarget. 6:28440–28452. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lu WJ, Chua MS and So SK: Suppression of
ATAD2 inhibits hepatocellular carcinoma progression through
activation of p53- and p38-mediated apoptotic signaling.
Oncotarget. 6:417222015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang M, Zhang C, Du W, Yang X and Chen Z:
ATAD2 is overexpressed in gastric cancer and serves as an
independent poor prognostic biomarker. Clin Transl Oncol.
18:776–781. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chou TF, Brown SJ, Minond D, Nordin BE, Li
K, Jones AC, Chase P, Porubsky PR, Stoltz BM, Schoenen FJ, et al:
Reversible inhibitor of p97, DBeQ, impairs both ubiquitin-dependent
and autophagic protein clearance pathways. Proc Natl Acad Sci USA.
108:4834–4849. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chou TF, Li K, Frankowski KJ, Schoenen FJ
and Deshaies RJ: Structure-activity relationship study reveals
ML240 and ML241 as potent and selective inhibitors of p97 ATPase.
Chem Med Chem. 8:297–312. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Magnaghi P, D'Alessio R, Valsasina B,
Avanzi N, Rizzi S, Asa D, Gasparri F, Cozzi L, Cucchi U, Orrenius
C, et al: Covalent and allosteric inhibitors of the ATPase
VCP/p97induce cancer cell death. Nat Chem Biol. 9:548–556. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Anderson DJ, Le Moigne R, Djakovic S,
Kumar B, Rice J, Wong S, Wang J, Yao B, Valle E, Kiss von Soly S,
et al: Targeting the AAA ATPase p97 as an approach to treat cancer
through disruption of protein homeostasis. Cancer Cell. 28:653–665.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Demont EH, Chung CW, Furze RC, Grandi P,
Michon AM, Wellaway C, Barrett N, Bridges AM, Craggs PD, Diallo H,
et al: Fragment-Based Discovery of Low-Micromolar ATAD2Bromodomain
Inhibitors. J Med Chem. 58:5649–5673. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bamborough P, Chung CW, Furze RC, Grandi
P, Michon AM, Sheppard RJ, Barnett H, Diallo H, Dixon DP, Douault
C, et al: Structure-based optimization of naphthyridones into
PotentATAD2 bromodomain inhibitors. J Med Chem. 58:6151–6178. 2015.
View Article : Google Scholar : PubMed/NCBI
|
